FDA approves Phase II of stem cell trial for ALS led by U-M’s Dr. Eva Feldman

April 18, 2013

For nearly two years, University of Michigan neurologist Eva Feldman, M.D., Ph.D. has led the nation’s first clinical trial of stem cell injections in patients with the deadly degenerative disease known as amyotrophic lateral sclerosis, often called ALS or Lou Gehrig’s disease. (Sacramento Bee)